Table 2.
Clinical and demographic characteristics of pathogenic germline variant carriers
| Positive (N = 38) | VUS/Negative (N = 212) | Total (N = 250) | P value | |
| Enrollment region | 0.356a | |||
| Southwest | 19 (14.4%) | 113 (85.6%) | 132 (100.0%) | |
| Midwest | 6 (11.1%) | 48 (88.9%) | 54 (100.0%) | |
| Southeast | 13 (20.3%) | 51 (79.7%) | 64 (100.0%) | |
| Sex | 0.334a | |||
| Male | 24 (17.1%) | 116 (82.9%) | 140 (100.0%) | |
| Female | 14 (12.7%) | 96 (87.3%) | 110 (100.0%) | |
| Age | 0.206b | |||
| Mean (SD) | 63.3 (8.5) | 65.3 (8.8) | 65.0 (8.7) | |
| Median | 66.0 | 67.0 | 66.5 | |
| Range | 44.0–78.0 | 38.0–80.0 | 38.0–80.0 | |
| Age group, yrs | 0.438a | |||
| Younger than 60 | 11 (28.9%) | 49 (23.1%) | 60 (24.0%) | |
| Aged 60 yrs or older | 27 (71.1%) | 163 (76.9%) | 190 (76.0%) | |
| Race | 0.453a | |||
| White | 32 (15.3%) | 177 (84.7%) | 209 (100.0%) | |
| Hispanic/Latino | 1 (5.9%) | 16 (94.1%) | 17 (100.0%) | |
| Black/African American | 2 (15.4%) | 11 (84.6%) | 13 (100.0%) | |
| Asian | 2 (50.0%) | 2 (50.0%) | 4 (100.0%) | |
| American Indian/Alaskan Native | 1 (25.0%) | 3 (75.0%) | 4 (100.0%) | |
| Native Hawaiian/Pacific Islander | 0 (0.0%) | 2 (100.0%) | 2 (100.0%) | |
| Other | 0 (0.0%) | 1 (100.0%) | 1 (100.0%) | |
| Smoking | 0.143a | |||
| Yes | 21 (18.9%) | 90 (81.1%) | 111 (100.0%) | |
| No | 17 (12.2%) | 122 (87.8%) | 139 (100.0%) | |
| BMI > 30 kg/m2 | 0.590a | |||
| Yes | 4 (12.1%) | 29 (87.9%) | 33 (100.0%) | |
| No | 34 (15.7%) | 183 (84.3%) | 217 (100.0%) | |
| Diabetes mellitus | 0.802a | |||
| Yes | 10 (14.3%) | 60 (85.7%) | 70 (100.0%) | |
| No | 28 (15.6%) | 152 (84.4%) | 180 (100.0%) | |
| Hypertension | 0.528a | |||
| Yes | 13 (13.4%) | 84 (86.6%) | 97 (100.0%) | |
| No | 25 (16.3%) | 128 (83.7%) | 153 (100.0%) | |
| Pedigree complete | 0.685a | |||
| Yes | 20 (16.1%) | 104 (83.9%) | 124 (100.0%) | |
| No | 18 (14.3%) | 108 (85.7%) | 126 (100.0%) | |
| Family history of cancer (any) in first-degree relatives | 0.587a | |||
| Yes | 13 (14.3%) | 78 (85.7%) | 91 (100.0%) | |
| No | 7 (21.2%) | 26 (78.8%) | 33 (100.0%) | |
| Family history of pancreatic cancer in first-degree relative | 0.598a | |||
| Yes | 2 (11.8%) | 15 (88.2%) | 17 (100.0%) | |
| No | 18 (16.8%) | 89 (83.2%) | 107 (100.0%) | |
| Proband/first-degree relative cancer match | 0.372a | |||
| Yes | 4 (11.4%) | 31 (88.6%) | 35 (100.0%) | |
| No | 16 (18.0%) | 73 (82.0%) | 89 (100.0%) | |
| Missing | 18 | 108 | 126 | |
| Staging AJCC 8th edition at diagnosis (clinical stage) | 0.473a | |||
| 1 | 6 (16.7%) | 30 (83.3%) | 36 (100.0%) | |
| 2 | 7 (14.0%) | 43 (86.0%) | 50 (100.0%) | |
| 3 | 6 (9.7%) | 56 (90.3%) | 62 (100.0%) | |
| 4 | 19 (18.6%) | 83 (81.4%) | 102 (100.0%) | |
| Location | 0.141a | |||
| Head | 22 (13.2%) | 145 (86.8%) | 167 (100.0%) | |
| Body | 6 (13.6%) | 38 (86.4%) | 44 (100.0%) | |
| Tail | 10 (25.6%) | 29 (74.4%) | 39 (100.0%) | |
| Deceased | 0.069a | |||
| Yes | 9 (23.7%) | 83 (39.2%) | 92 (36.8%) | |
| No | 29 (76.3%) | 129 (60.8%) | 158 (63.2%) |
AJCC, American Joint Committee on Cancer; BMI, body mass index; VUS, variant of uncertain significance.
a
The Pearson χ2 test.
b
Linear model analysis of variance.